Business Description
Poxel SA
ISIN : FR0012432516
Compare
Compare
Traded in other countries / regions
POXEL.France0RA2.UK7PO.GermanyPXXLF.USA IPO Date
2015-02-05Description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | -10.18 | |||||
| Debt-to-Equity | -0.96 | |||||
| Debt-to-EBITDA | -4.92 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -45.48 | |||||
| Beneish M-Score | -21.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -38 | |||||
| 3-Year EBITDA Growth Rate | 30.4 | |||||
| 3-Year EPS without NRI Growth Rate | 4 | |||||
| 3-Year FCF Growth Rate | 23.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.18 | |||||
| 9-Day RSI | 16.53 | |||||
| 14-Day RSI | 17.76 | |||||
| 3-1 Month Momentum % | -53.15 | |||||
| 6-1 Month Momentum % | -56.95 | |||||
| 12-1 Month Momentum % | -24.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.34 | |||||
| Quick Ratio | 0.34 | |||||
| Cash Ratio | 0.18 | |||||
| Days Sales Outstanding | 163.26 | |||||
| Days Payable | 308.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 | |||||
| Shareholder Yield % | -109 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 0.78 | |||||
| Operating Margin % | -420.38 | |||||
| Net Margin % | -736.06 | |||||
| FCF Margin % | -638.85 | |||||
| ROA % | -92.3 | |||||
| ROIC % | -40.01 | |||||
| 3-Year ROIIC % | -5.38 | |||||
| ROC (Joel Greenblatt) % | -1264.01 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.53 | |||||
| EV-to-EBIT | -5.27 | |||||
| EV-to-EBITDA | -5.43 | |||||
| EV-to-Revenue | 23.69 | |||||
| EV-to-FCF | -3.71 | |||||
| Price-to-GF-Value | 0.14 | |||||
| Earnings Yield (Greenblatt) % | -18.98 | |||||
| FCF Yield % | -195.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Poxel SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.188 | ||
| EPS (TTM) (€) | -0.379 | ||
| Beta | 1.53 | ||
| 3-Year Sharpe Ratio | -1.26 | ||
| 3-Year Sortino Ratio | -1.44 | ||
| Volatility % | 90.12 | ||
| 14-Day RSI | 17.76 | ||
| 14-Day ATR (€) | 0.019545 | ||
| 20-Day SMA (€) | 0.1977 | ||
| 12-1 Month Momentum % | -24.2 | ||
| 52-Week Range (€) | 0.115 - 0.95 | ||
| Shares Outstanding (Mil) | 53.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Poxel SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Poxel SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Poxel SA Frequently Asked Questions
What is Poxel SA(XPAR:POXEL)'s stock price today?
The current price of XPAR:POXEL is €0.13. The 52 week high of XPAR:POXEL is €0.95 and 52 week low is €0.12.
When is next earnings date of Poxel SA(XPAR:POXEL)?
The next earnings date of Poxel SA(XPAR:POXEL) is 2025-04-09 Est..
Does Poxel SA(XPAR:POXEL) pay dividends? If so, how much?
Poxel SA(XPAR:POXEL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers